Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool

NCT02982486 is registered in ClinicalTrials.gov with Assaf-Harofeh Medical Center as lead sponsor.

NCT NCT02982486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02982486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool
Lead sponsor
Assaf-Harofeh Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2017
Completion date
December 31, 2020
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone sarcoma, chondrosarcoma, desmoplastic small round cell tumor, ewing's tumor metastatic, ewing's tumor recurrent, gastrointestinal stromal sarcoma, osteosarcoma, soft tissue sarcoma